Apixaban (Eliquis) for Stroke Prevention in Atrial Fibrillation
Frontiers | Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy
Low-dose apixaban safe, effective as secondary prophylaxis for VTE in patients with cancer
Target-Specific Oral Anticoagulants
Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week - ScienceDirect
Target-Specific Oral Anticoagulants
Eliquis: Package Insert / Prescribing Information - Drugs.com
Missouri Society of Health-System Pharmacists - Pharmacist Continuing Education: From DOACs to ROACs: Strategies for Reversing Oral Anticoagulants
Safety and effectiveness of reduced-dose apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A sub-analysis of the STANDARD study - Journal of Cardiology
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer | NEJM
Apixaban (Eliquis®) – Drug-Drug-Interaction Considerations in COVID-19 Patients with Coagulation Abnormalities - Anesthesia Patient Safety Foundation
Venous thromboembolism: current management - Australian Prescriber
ELIQUIS® (apixaban) dosing for DVT & PE patients | ELIQUIS UK
Anticoagulation therapy in Atrial Fibrillation patients at high bleeding risk
Eliquis (Apixaban Tablets): Uses, Dosage, Side Effects, Interactions, Warning
Antithrombotic Management of Venous Thromboembolism: JACC Focus Seminar - ScienceDirect
Apixaban starting dose after 1 week LMWH therapy (PE or DVT)? | ResearchGate
Health Canada dosing regimens for the treatment of venous... | Download Scientific Diagram
Update on the New Oral Anticoagulants - ppt video online download
Health Canada dosing algorithm for apixaban according to renal... | Download Scientific Diagram
Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients | American Society of Nephrology
apixaban - Twitter 搜尋 / Twitter
Quick reference guide to apixaban | VHRM
ELIQUIS® (apixaban) dosing for NVAF patients | ELIQUIS UK
